rethinkTHC Search
Menu
Study breakdown

CB2 Receptor Activation Emerges as Promising Target for Treating Gum Disease

Systematic ReviewPreliminary evidence
The takeaway

A systematic review of 9 studies found that CB2 receptor activation reduced inflammation and bone loss in periodontitis, while CB1 showed minor changes in diseased gum tissue.

periodontists, dental researchers, cannabinoid pharmacologists

What the researchers found

CNR2 (CB2) gene expression was significantly reduced in periodontitis tissue. Animal studies showed CB2 activation increased receptor expression, reduced pro-inflammatory cytokines, and mitigated alveolar bone loss. CB1 activation also reduced inflammation and bone loss. Bioinformatics analysis revealed CB1 and CB2 have distinct but complementary roles in periodontal inflammation.

Why it matters

Periodontitis affects a large portion of the global population and can lead to tooth loss. Identifying the endocannabinoid system as a modulator of gum inflammation opens a new therapeutic avenue that could complement existing treatments.

The numbers in context

9 studies included (3 clinical, 6 preclinical). 5 databases searched. CNR2 expression significantly reduced in periodontitis. CB2 activation reduced cytokines and bone loss in animals. Anandamide showed anti-inflammatory effects. CNR1 positively associated with B-cell activation genes. CNR2 correlated with immune regulation and extracellular matrix remodeling.

How the study worked

Systematic review searching PubMed/MEDLINE, Embase, Web of Science, Scopus, and Cochrane Library for studies on periodontitis and endocannabinoid system through August 2024. 9 studies met inclusion criteria (3 clinical, 6 preclinical). Supplemented with in silico analysis using GSE16134 dataset for gene expression and pathway analysis.

What this study cannot tell us

Only 9 studies met criteria, mostly preclinical. Heterogeneous study designs. Clinical studies were small. In silico analyses are hypothesis-generating, not confirmatory. No clinical trials of cannabinoid-based periodontal treatments exist.

How to read the evidence

Systematic review methodology is rigorous, but only 9 studies (mostly preclinical) and no clinical treatment trials limit evidence to preliminary.

When this study was published

Literature search through August 2024.

The bigger picture

This review bridges cannabinoid pharmacology and dentistry, a relatively unexplored intersection. While primarily preclinical, the findings suggest CB2-targeted therapies could eventually become part of periodontal treatment strategies.

Questions still open

  • Could topical cannabinoid formulations treat gum disease?
  • Does recreational cannabis use affect periodontal health through these pathways?

Common questions

Could cannabis help with gum disease?
The endocannabinoid system, which cannabis interacts with, appears to play a role in gum inflammation. CB2 receptor activation reduced inflammation in animal studies, but no human treatment trials exist yet.
Does smoking cannabis affect gum health?
This review focused on the endocannabinoid system's role in periodontal disease, not on smoking effects. Cannabis smoke itself has known negative effects on oral health separate from endocannabinoid signaling.

Read the original research

Endocannabinoid system in periodontitis: A systematic review and in silico analyses.

Archives of oral biology, 179, 106394

Citation

Soares, Lélio Fernando Ferreira; Oliveira, Jovânia Alves; Nogueira, Andressa Vilas Boas; Júnior, Carlos Rossa; Pigossi, Suzane Cristina; Deschner, James; Cirelli, Joni Augusto. (2025). Endocannabinoid system in periodontitis: A systematic review and in silico analyses.. Archives of oral biology, 179, 106394. https://doi.org/10.1016/j.archoralbio.2025.106394

Explore the wider topic